^

Association details:

Drug Class:
Direction:
Resistant

Evidence:

Evidence Level:
Resistant: C3 – Early Trials
New
Title:
A low tumor mutational burden and PTEN mutations are predictors of a negative response to PD-1 blockade in MSI-H/ dMMR gastrointestinal tumors
Published date:
04/29/2021
Excerpt:
Forty-five patients with MSI-H/dMMR GI tumors, including gastric cancer, colorectal cancer, cholangiocarcinoma, small intestine cancer, pancreatic cancer, and duodenal cancer, receiving PD-1 blockade were analyzed....Patients with low tumor mutational burdens (TMBs) had lower objective response rates (ORRs) (0 vs 48.8%) and a significantly shorter progression-free survival (PFS) (2.3 vs 15.6 months; hazard ratio (HR): 6.20, P = 0.002) than those with high TMBs....Low TMBs and PTEN mutations...negative predictors of PD-1 blockade responses in patients with MSI-H/dMMR GI tumors.
DOI:
10.1158/1078-0432.CCR-21-0401
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our